Journal
PEDIATRIC DERMATOLOGY
Volume 39, Issue 3, Pages 432-433Publisher
WILEY
DOI: 10.1111/pde.14965
Keywords
chronic skin graft-versus-host disease; corticosteroid-refractory graft-versus-host disease; hematopoietic stem cell transplant; ruxolitinib
Categories
Ask authors/readers for more resources
Chronic graft-versus-host disease (cGVHD) of the skin is a serious cause of long-term morbidity and mortality among patients who receive hematopoietic stem cell transplants. There is currently no consensus on second-line therapy for steroid-refractory disease. This case report presents successful treatment of a pediatric patient with severe cGVHD of the skin, nonresponsive to corticosteroids, using a prolonged course of ruxolitinib with minimal side effects.
Chronic graft-versus-host disease (cGVHD) of the skin is a serious cause of long-term morbidity and mortality among patients who receive hematopoietic stem cell transplants. Systemic corticosteroids remain first-line treatment for cutaneous cGVHD; however, there is currently no consensus on second-line therapy for steroid-refractory disease. We herein present a case of a pediatric patient with severe cGVHD of the skin, nonresponsive to corticosteroids, who was successfully treated with a prolonged course of ruxolitinib with minimal side effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available